

Serum lipid profile changes and their clinical diagnostic significance in COVID-19 Mexican Patients

Juan Fidel Osuna-Ramos^{1**}, Horacio Rendón-Aguilar², Luis Adrián De Jesús-González¹, José Manuel Reyes-Ruiz¹, Arely Montserrat Espinoza-Ortega², Luis Antonio Ochoa-Ramírez², Alejandra Romero-Utrilla³, Efrén Ríos-Burgueño⁴, Alejandro Soto-Almaral², Juan José Ríos-Tostado⁵, José Geovanni Romero-Quintana⁶, Héctor Ponce-Ramos², Carlos Noe Farfan-Morales¹, Rosa María del Ángel¹, Héctor Barajas-Martínez⁷, José Rodríguez-Millán², Jesús Salvador Velarde-Félix^{2,5*}

1. Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico
2. Hospital General de Culiacán, Culiacán, Sinaloa, México
3. Departamento de anatomía patológica, Instituto Mexicano del Seguro Social (IMSS). Culiacan, Sinaloa, Mexico.
4. Departamento de anatomía patológica, Centro de Investigación y Docencia en Ciencias de la Salud, Universidad Autónoma de Sinaloa, Hospital Civil de Culiacán, , México.
5. Escuela de Biología, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa. México
6. Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, México.

7. Lankenau Heart Institute, Sidney Kimmel College of Medicine, Thomas Jefferson University, USA.

*Corresponding author:

E-mail address: jsvelfe@hotmail.com; jsvelfe@uas.edu.mx (JS Velarde-Félix)

Hospital General de Culiacán “Bernardo J. Gastélum”. Juan Aldama y Nayarit s/n.

Col. Rosales. 802030. Culiacán, Sinaloa, México. CP: 80230.

**Co-corresponding author:

E-mail address: osram90@gmail.com; jfosuma@cinvestav.mx (JF Osuna-Ramos)

Abstract

Background: COVID-19 has been recognized as an emerging and rapidly evolving health condition. For this reason, efforts to determine changes in laboratory parameters of COVID-19 patients as biomarkers are urgent. Lipids are essential components of the human body, and their modulation has been observed implicated in some viral infections.

Methods: To evaluate the clinical diagnosis utility of the lipid profile changes in Mexican COVID-19 patients, the lipid profile of one hundred two COVID-19 positive patients from three hospitals in Culiacan, Sinaloa in northwest Mexico, was analyzed. ROC curves and binary logistic regression analysis were used as a predictive model to determine their clinical diagnostic utility.

Results: Significant changes in the serum lipid profile of patients with COVID-19, such as low levels of cholesterol, LDL, and HDL, while high triglycerides and VLDL were observed. The same abnormalities in the lipid profile among non-critical and critical COVID-19 patients were detected. The predictive model analysis suggests that cholesterol and LDL have AUC values of 0.710 and 0.769, respectively, for COVID-19 ($p= 0.0002$ and $p= <0.0001$), and LDL low levels might be a risk factor for critical COVID-19 (OR= 2.07, 95% IC: 1.18 to 3.63; $p= 0.01$).

Conclusion: Our findings suggest that low cholesterol and LDL levels could be considered an acceptable predictor for COVID-19, and low levels of LDL might be a risk factor for critical COVID-19 patients.

Keywords: COVID-19, Serum Lipid Profile, ROC curves, Biomarkers

1. Introduction

Coronavirus disease 2019 (COVID-19) is a public health emergency of international concern caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). More than two hundred countries around the world have reported more than 13 million confirmed cases, and more than half a million deaths caused by COVID-19^{1,2}. The epidemiological information of the COVID-19 pandemic in Latin America indicates that as of June nearly four million cases and more than two hundred thousand deaths have been reported³, while in Mexico, 311, 486 cases of COVID-19 and 36,327 deaths have been reported^{4,5}. The SARS-CoV-2 transmission was initially linked to a local exotic animal market in the province of Wuhan, China, indicating a possible zoonosis⁶. SARS-CoV-2 can be transmitted human-to-human, through the inhalation of aerosols with nasal discharge droplets, in addition to direct or indirect contact of the oral and nasal mucous membranes and eye membranes with everyday contaminated objects⁷⁻¹⁰. The symptoms of the disease may be mild (flu-like infection with fever, headache or dry cough) or severe due to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), leading to acute breathing difficulties, respiratory failure, multiple organ failure, or death of the patient⁹⁻¹¹. Reports of patients with associated morbidity, mainly diabetes (DM), hypertension (HT), and other cardiovascular and cerebrovascular diseases, have been linked to poor prognosis of the disease¹²⁻¹⁴.

Additionally, manifestations of hypolipidemia were reported in Chinese patients with mild symptoms and progressively worsened according to the severity of the disease^{15,16}. The severity of the disease could be attributed to alterations in

cholesterol levels since mainly two groups of the population are more affected in morbidity and mortality by COVID-19¹⁷⁻²¹. On the other hand, changes in serum lipid profiles have been reported previously in other viral infections²²⁻²⁶, including respiratory viral infections, where their potential as metabolic biomarkers to help clinicians distinguish bacterial from viral infection in febrile patients has been determined²⁷. For these reasons, we found it interesting to explore whether alterations in serum lipid levels in COVID-19 Mexican patients can be useful as biomarkers of disease or severity. In this study, we analyzed the lipid profile of one hundred two COVID-19 positive patients from 3 hospitals in Culiacan, Sinaloa, in northwest Mexico, one of the states with the highest number of cases of the disease in Mexico, and using a combination of ROC curves and logistic regression analysis we evaluate the clinical diagnosis utility of the lipid profile in Mexican COVID-19 patients.

1. Material and methods

2.1 Study design

A prospective and descriptive study was conducted at three different hospitals from Culiacan, Sinaloa, in northwest Mexico, from April 16 to June 16, 2020. All patients included in this study met the diagnostic criteria according to national and international guidelines for the diagnosis and treatment of COVID-19^{27,28}, and the SARS CoV-2 infection was confirmed by the real-time polymerase chain reaction (RT-PCR) test. The information for all patients was obtained from electronic medical record systems, except the lipid profile (total serum cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, and VLDL).

The risk stratification was determined according to the symptoms and clinical signs presented by the patients. In the mild disease with mild COVID-19, patients suffered of fever, headache, cough, respiratory symptoms, or chest pain, while in severe cases, patients have a respiratory rate (RR) ≥ 30 per minute or/and oxygen saturation ≤ 93 %. Critical COVID-19 patients met severe case criteria plus the need for mechanical ventilation, or/and had a shock or multiorgan failure ²⁹. Additionally, to dichotomize the variables and calculate risks and diagnostic accuracy, patients were divided into non-critical COVID-19 patients and critical COVID-19 patients: non-critical COVID-19 patients were those patients classified as mild or severe COVID-19 cases.

2.2 Serum Lipid Profile quantification

A fasting blood sample was taken from each participant at hospital admission to determine the total serum cholesterol (n= 102), low-density lipoprotein (LDL) (n= 94), high-density lipoprotein (HDL) (n= 93), and triglycerides (n= 98) levels by enzymatic method. Very-low-density lipoprotein (VLDL) (n= 98) levels were measured using Friedewald's methodology ³⁰.

Additionally, the lipid profile data of a group of thirty healthy blood donors, who were part of a previous pre-pandemic study [32], was used as healthy controls. The control subjects were negative for a viral panel (anti-dengue IgM and IgG, HIV, HCV antibodies) and belonged to the same geographic region. They had no previous history of dyslipidemia or a history of cholesterol-lowering therapy.

The Research Ethical Committee of Hospital General de Culiacan "Bernardo J Gastelum" approved the study, and some patients writing informed consent, and in another, the consent was verbal.

2.3 Statistic analysis

The data were expressed as median and interquartile ranges (IQR, 25-75th percentile) to describe age, and mean and standard deviation (SD) were used to describe the lipid profile. The parametric Unpaired t-test with Welch's correction was used to compare the lipid profile means of total COVID-19 patients between healthy controls, and the non-parametric U Mann Whitney test was used to compare age and lipid profile median values among non-critical and critical COVID-19 patients, using the GraphPad Prism software version 7. To determine if changes in the serum lipid profile are useful to predict COVID-19 disease or severity, receiver operating characteristic (ROC) curves and area under the curves ROC (AUC) were calculated to evaluate the sensitivity, specificity, positive (+LR) and negative (-LR) likelihood ratios to each lipid in the lipid profile in predicting COVID-19 disease and critical COVID-19. Moreover, binary logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (95% IC) between non-critical and critical COVID-19 patients based on the calculated optimal cut-off points using the MedCalc software version 14. Statistical significance was set at $p < 0.05$.

3. Results

During the study period, clinical and lipid profile information was obtained from 102 COVID-19 patients. Their demographic data showed a median age of 57 years and a higher frequency of male patients at hospital admission (Table 1). The patient stratification was according to the risk, based on the clinic, as shown in Table 1. Age differs significantly between non-critical and critical COVID-19 cases ($p=0.0095$), and males were more frequent among non-critical and critical COVID-19 patients. About comorbidities, hypertension (HT), obesity, and diabetes (DM) were the most frequent, especially in the critical COVID-19 group of patients (Table 1).

	All patients (n = 102)	Non-critical COVID-19 (n = 64)	Critical COVID- 19 (n = 38)
Age, median years (IQR)	57 (45.75 – 64)	54 (41.25 – 62)	60.5 (51 – 69)
Sex, number of patientes (%)			
Female	37 (36.3)	24 (37.5)	13 (34.2)
Male	65 (63.7)	40 (62.5)	25 (65.8)
Clinical features, number (%)			
RR \geq 30	28 (27.5)	12 (18.8)	16 (42.1)
SatO ₂ \leq 93 %	65 (63.7)	37 (57.8)	28 (73.7)
Intubation	33 (86.8)	0	33 (86.8)
Shock	17 (16.7)	0	17 (44.7)
Comorbidities, number (%)			
HT	59 (57.8)	31 (48.4)	28 (73.7)
DM	37 (36.3)	21 (32.8)	16 (42.1)
Obesity	44 (43.1)	28 (43.8)	16 (42.1)

Table 1. Demographic and clinical characteristics of COVID-19 patients. RR= respiration rate, SatO₂= Oxygen Saturation, HT= Hypertension, DM= Diabetes.

Regarding to the lipid profile in COVID-19 patients, the mean cholesterol (126 ± 41.02 mg/dL), LDL (69.5 ± 34.9 mg/dL) and HDL (29.9 ± 12.19 mg/dL) levels were lower compared to healthy control group (157.7 ± 37.1 mg/dL, LDL: 100.6 ± 27.64 mg/dL and 41.43 ± 15.01 mg/dL, respectively) (Figure 1). On the other hand, both mean triglyceride (155.4 ± 72.49 mg/dL) and VLDL (31.09 ± 14.5 mg/dL) levels were higher in COVID-19 patients compared to healthy control (115 ± 65.07 mg/dL and 23 ± 13.01 mg/dL) (Figure 1).




Figure 1. Lipid profile in COVID-19 patients (black circles) compared with healthy controls (Gray circles). In blue is showed the mean line and SD error bars lines.

The output analysis is represented as the following p-values means differences:

0.0332 (*), 0.0021 (**), 0.0002 (***), <0.0001 (****).

To establish if differences between the lipid profile can accurately use to distinguish between COVID-19 patients and healthy individuals, ROC curves were used to determine optimal cut-off points and AUC for each lipid parameter. Based on Youden's J index, the results of the ROC analysis, optimal cut-off, and the AUC calculations are shown in Table 2. Cholesterol and LDL showed optimal predictive value as well as higher sensitivity (greater than 60%) and specificity (greater than 80%) and AUC values of 0.710 and 0.769, respectively (Table 2).

	Cut-off point	Sensitivity (95% CI)	Specificity (95% CI)	+LR (95% CI)	-LR (95% CI)	Youden Index J	AUC (95% CI)	p-value
Cholesterol	≤142	69.61 (59.7 - 78.3)	80 (61.4 - 92.3)	3.48 (1.7 - 7.2)	0.38 (0.3 - 0.5)	0.4961	0.710 (0.625 - 0.786)	0.0002
LDL	≤85	72.34 (62.2 - 81.1)	80 (61.4 - 92.3)	3.62 (1.7 - 7.5)	0.35 (0.2 - 0.5)	0.5234	0.769 (0.684 - 0.840)	<0.0001
HDL	≤28	48.39 (37.9 - 59.0)	93.33 (77.9 - 99.2)	7.26 (1.9 - 28.1)	0.55 (0.4 - 0.7)	0.4172	0.719 (0.630 - 0.796)	<0.0001
Triglycerides	>114	67.35 (57.1 - 76.5)	63.33 (43.9 - 80.1)	1.84 (1.1 - 3.0)	0.52 (0.3 - 0.8)	0.3068	0.679 (0.591 to 0.759)	0.0023
VLDL	>22.8	67.35 (57.1 - 76.5)	63.33 (43.9 - 80.1)	1.84 (1.1 - 3.0)	0.52 (0.3 - 0.8)	0.3068	0.679 (0.591 to 0.759)	0.0023

Table 2. Optimal Cut-off point and AUCs predictors for the lipid profile in COVID-19 patients. +LR= positive likelihood ratio, -LR= negative likelihood ratio, AUC= area under the curve.

In further analysis, to determine if there were differences between the lipid profile in COVID-19 patients according to severity, non-critical and critical. Lower cholesterol (119 mg/dL, IQR: 94.5 - 154.5 mg/dL, n= 38), LDL (50 mg/dL, IQR: 33 - 87.75 mg/dL, n= 36), and HDL (26 mg/dL, IQR: 16-43 mg/dL, n= 35) values were observed in critical compared with non-critical patients (cholesterol: 125 mg/dL, IQR: 102 - 160.8, n= 64; LDL: 69 mg/dL, IQR: 48.25- 95.25 mg/dL, n= 58; HDL: 30 mg/dL, IQR: 22 - 36.5 mg/dL, n= 61), while median values of triglycerides (145 mg/dL, IQR: 100.5 - 201.5 mg/dL, n= 37) and VLDL in critical patients were higher than median triglycerides and VLDL values in no-critical (138 mg/dL, IQR: 103 – 105 mg/dL, n= 61, and 27.6 mg/dL, IQR: 20.6 - 41 mg/dL, for triglycerides and VLDL, respectively). However, only median LDL values differences were statistically significant among non-critical and critical COVID-19 patients (Figure 2).




Figure 2. Lipid profile compared between no-critical (gray) and critical (black) COVID-19 patients. In blue is showed the median line and IQR error bars lines. The output analysis is represented as the following p-values mean differences:

0.0332 (*).

Moreover, a combination of ROC curves and binary logistic regression analysis was performed as a predictive model. The optimal working point was for LDL and showed predictive values of 50% sensitivity and 75% specificity, as well as an AUC of 0.621, with an optimal cut-off value ≤ 48 mg/dL, to discriminate between non-critical and critical COVID-19 (Table 3).

	Cut-off point	Sensitivity (95% CI)	Specificity (95% CI)	+LR (95% %)	-LR (95% %)	Youden Index J	AUC (95% CI)	p-value
--	---------------	----------------------	----------------------	-------------	-------------	----------------	--------------	---------

				CI)	CI)			
Cholesterol	≤99	36.84 (21.8 - 54.0)	78.12 (66.0 - 87.5)	1.68 (0.9 - 3.1)	0.81 (0.6 - 1.1)	0.1497	0.557 (0.45 5 to 0.655)	0.344 4
LDL	≤48	50.00 (32.9 - 67.1)	75.86 (62.8 - 86.1)	2.07 (1.2 - 3.6g)	0.66 (0.5 - 0.9)	0.2586	0.621 (0.51 5 to 0.719)	0.054 2
HDL	≤25	48.57 (31.4 - 66.0)	71.19 (57.9 - 82.2)	1.69 (1.0 - 2.9)	0.72 (0.5 - 1.0)	0.1976	0.536 (0.43 0 to 0.639	0.599 6
Triglyceride s	>251	13.51 (4.5 - 28.8)	95.08 (86.3 - 99.0)	2.75 (0.7 - 10.8)	0.91 (0.8 - 1.0)	0.0859 5	0.511 (0.40 8 to 0.613)	0.856 8
VLDL	>50. 2	13.51 (4.5 - 28.8)	95.08 (86.3 - 99.0)	2.75 (0.7 - 10.8)	0.91 (0.8 - 1.0)	0.0859 5	0.511 (0.40 8 to 0.613)	0.856 8

Table 3. Optimal Cut-off point and AUCs predictors for critical COVID-19 patients.

+LR= positive likelihood ratio, -LR= negative likelihood ratio, AUC= area under the curve

On the other hand, the binary logistic regression analysis on the correlations showed that LDL ≤ 48 mg/dL cut-off value might be a risk factor for critical COVID-19 (OR= 2.07, 95% IC: 1.18 to 3.63; p= 0.01) (Table 4).

Variable, cut-off point	OR	95% IC	P value
Cholesterol, ≤99	1.68	0.90 - 3.13	0.10
LDL, ≤48	2.07	1.18 - 3.63	0.01

HDL, ≤ 25	1.76	1.02 - 3.01	0.04
Triglycerides, >251	2.74	0.69 - 10.83	0.13
VLDL, >50.2	2.74	0.69 - 10.83	0.13

Table 4. Binary logistic regression analysis of lipid profile associated with critical COVID-19 based on the optimal cut-off values. OR= odd ratio, 95% IC =95% Interval confidence, SE= standard error.

4. Discussion

Lipids are essential components of the human body, and they are involved in metabolic diseases such as diabetes, which is characterized by elevated total cholesterol, LDL, HDL, and triglycerides serum levels^{31,32}. Also, increased serum levels of cholesterol, triglycerides, LDL and decreased HDL are known to be associated with the significant risk factors for Cardiovascular Disease and hypertension³³. Interestingly, changes in serum lipid profiles are prognostic indicators of diseases, including viral infections. In this sense, clinical research indicates that patients infected with human immunodeficiency (HIV)²², dengue (DENV)²³⁻²⁵, and hepatitis B (HBV)²⁶ viruses develop hypocholesterolemia and hypertriglyceridemia, as well as low levels of LDL or HDL.

A recently published study performed in China found that LDL and total cholesterol levels were significantly lower in COVID-19 patients as compared with the control group ¹⁵. In the same way of evidence, Fan et al. reported a similar pattern of low cholesterol, LDL, and HDL levels in a group of 21 patients with COVID-19 in Wuhan, China ¹⁶. Therefore, it appears that there is a pattern of dyslipidemia that may be characteristic of patients with COVID-19. However, it is true that worldwide there is a wide variation in serum lipid profile levels depending on the different population groups ³³.

In the present study, conducted in a Mexican population, significant changes in the lipid profile of patients with COVID-19 was found. The same pattern of dyslipidemia observed in previously reported studies in Asia was also observed in the Mexican population ^{15,16}, as low levels of cholesterol, LDL, and HDL, while high levels of triglycerides and VLDL when compared with a group of healthy individuals. This repeating pattern in lipid profile changes in COVID-19 patients made us propose the lipid profile changes as a possible biomarker for COVID-19. Therefore, through a predictive model using ROC curves, we were able to detect the optimal cut-off points of ≤ 99 mg/dL for cholesterol and ≤ 48 mg/dL for LDL, which could be considered acceptable predictors for COVID-19 since they demonstrated to have significant AUC values between 0.70 and 0.80 for diagnostic accuracy ³⁴.

Serum dyslipidemia during the COVID-19 may be due to the role of lipids in SARS-Cov-2 replication in the host cell since they participate in the internalization of the virus into the cell ³⁵⁻³⁷, and in the dynamism of the lipid rafts in the membrane

where the ACE-2 receptor is located^{38,39}. Also, SARS-CoV-2 regulates the lipidic metabolism to generate viral membrane and pack its genome and in the exocytosis of the virions^{40,41}. For this reason, a growing recent interest in the lipids changes research has been noted in SARS-CoV-2 infected patients, since people with metabolic diseases such as DM, HT, and obesity, possibly leading to a higher risk of complications and mortality from COVID-19^{42,43}. Our study found high frequencies of comorbidities alone or in combination, such as HT, DM, and obesity in COVID-19 patients. One of the main concerns of the Institute of Public Health is the high prevalence of these comorbidities in the Mexican population^{44,45}.

At this moment, COVID-19 is considering as an emerging and rapidly evolving condition. So, efforts to determine the change in laboratory parameters as biomarkers have been directed towards the identification of severe or critical cases of COVID-19^{46,47}. In this regard, we stratified into non-critical and critical patients, and the same pattern of low levels of cholesterol, LDL, and HDL was observed in critical COVID-19 patients.

The above is in concordance with observed by Wei et al. previously reported¹⁵. They divided COVID-19 patients per their severity into mild, severe, and critical categories. They found that the development of hypolipidemia begins in patients with mild symptoms and progressively worsens in association with the severity of the disease¹⁵. However, they reported that triglyceride levels decreased significantly in critical cases compared to mild and severe cases. Contrary to our results, as higher triglyceride levels were found in critically ill patients with COVID-

19, but only median LDL levels differences were statistically different between non-critical and critical patients. In another similar research, Fan et al., besides reporting a pattern of dyslipidemia similar to what has previously been observed in patients with COVID-19, they also showed that degrees of decrease in LDL levels are highly likely to be associated with the severity and mortality of the disease ¹⁶. The optimal cut-off point was for LDL in the ROC analysis, and we observed that LDL might be a risk factor for critical COVID-19. Because of the low AUC value obtained for LDL, it could not be considered an acceptable biomarker to differentiate between non-critical and critical COVID-19 patients. This may be due to the limitations of our study, such as sample size or the low statistical power difference observed between both groups of patients. However, it cannot be ruled out that LDL levels may be useful for decision making in the evolution of COVID-19 critically ill patients, and more studies are needed, especially in high-risk populations.

Funding

None.

Declaration of Competing Interest

None.

Acknowledgments

Juan Fidel Osuna-Ramos, Luis Adrián De Jesús-González, José Manuel Reyes-Ruiz and Carlos Noe Farfan-Morales received scholarships from CONACYT.

References

1. WHO Coronavirus Disease (COVID-19) Dashboard. Accessed June 16, 2020.
<https://covid19.who.int/>
2. Coronavirus Update (Live): 8,257,535 Cases and 445,986 Deaths from COVID-19 Virus Pandemic - Worldometer. Accessed June 16, 2020.
https://www.worldometers.info/coronavirus/?utm_campaign=homeAdUOA?Si
3. Cumulative COVID-19 cases reported by countries and territories in the Americas. Accessed June 16, 2020.
<https://who.maps.arcgis.com/apps/webappviewer/index.html?id=2203b04c3a5f486685a15482a0d97a87&extent=-17277700.8881%2C-1043174.5225%2C-1770156.5897%2C6979655.9663%2C102100>
4. COVID-19 Tablero México. COVID - 19 Tablero México. Accessed June 16, 2020. <http://datos.covid-19.conacyt.mx/index.php>
5. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents*. 2020;55(3):105924. doi:10.1016/j.ijantimicag.2020.105924
6. Chang D, Lin M, Wei L, et al. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. *JAMA*. 2020;323(11):1092-1093. doi:10.1001/jama.2020.1623
7. Cai J, Sun W, Huang J, Gamber M, Wu J, He G. Indirect Virus Transmission in Cluster of COVID-19 Cases, Wenzhou, China, 2020. *Emerg Infect Dis*. 2020;26(6):1343-1345. doi:10.3201/eid2606.200412

8. Zhang Z, Zhang L, Wang Y. COVID-19 indirect contact transmission through the oral mucosa must not be ignored. *J Oral Pathol Med.* 2020;49(5):450-451. doi:10.1111/jop.13019
9. Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. *Mil Med Res.* 2020;7. doi:10.1186/s40779-020-00240-0
10. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *J Adv Res.* 2020;24:91-98. doi:10.1016/j.jare.2020.03.005
11. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. *Am J Gastroenterol.* 2020;115. doi:10.14309/ajg.0000000000000620
12. Wang T, Du Z, Zhu F, et al. Comorbidities and multiorgan injuries in the treatment of COVID-19. *Lancet Lond Engl.* 2020;395(10228):e52. doi:10.1016/S0140-6736(20)30558-4
13. Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J.* 2020;55(5). doi:10.1183/13993003.00547-2020
14. Du Y, Tu L, Zhu P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. *Am J Respir Crit Care Med.* 2020;201(11):1372-1379. doi:10.1164/rccm.202003-0543OC

15. Wei X, Zeng W, Su J, et al. hypolipidemia is associated with the severity of COVID-19. *J Clin Lipidol*. Published online April 30, 2020.
doi:10.1016/j.jacl.2020.04.008
16. Fan J, Wang H, Ye G, et al. Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. *Metabolism*. 2020;107:154243. doi:10.1016/j.metabol.2020.154243
17. Shahid Z, Kalayanamitra R, McClafferty B, et al. COVID-19 and Older Adults: What We Know. *J Am Geriatr Soc*. 2020;68(5):926-929.
doi:10.1111/jgs.16472
18. Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. *GeroScience*. Published online April 10, 2020:1-10. doi:10.1007/s11357-020-00186-0
19. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet Lond Engl*. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
20. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. *Cardiovasc Res*. Published online April 30, 2020. doi:10.1093/cvr/cvaa106
21. Chakraborty H. Membrane cholesterol and SARS-CoV-2 infection: a possible connection. *Curr Sci*. 2020;118(8):1157.

22. Funderburg NT, Mehta NN. Lipid Abnormalities and Inflammation in HIV Infection. *Curr HIV/AIDS Rep.* 2016;13(4):218-225. doi:10.1007/s11904-016-0321-0
23. Osuna-Ramos JF, Rendón-Aguilar H, Reyes-Ruiz JM, et al. The correlation of TNF alpha levels with the lipid profile of dengue patients. *J Med Virol.* Published online February 15, 2018. doi:10.1002/jmv.25056
24. Durán A, Carrero R, Parra B, et al. Association of lipid profile alterations with severe forms of dengue in humans. *Arch Virol.* 2015;160(7):1687-1692. doi:10.1007/s00705-015-2433-z
25. Lima WG, Souza NA, Fernandes SOA, Cardoso VN, Godói IP. Serum lipid profile as a predictor of dengue severity: A systematic review and meta-analysis. *Rev Med Virol.* Published online June 6, 2019:e2056. doi:10.1002/rmv.2056
26. Cao W-J, Wang T-T, Gao Y-F, Wang Y-Q, Bao T, Zou G-Z. Serum Lipid Metabolic Derangement is Associated with Disease Progression During Chronic HBV Infection. *Clin Lab.* 2019;65(12). doi:10.7754/Clin.Lab.2019.190525
27. Wang X, Nijman R, Camuzeaux S, et al. Plasma lipid profiles discriminate bacterial from viral infection in febrile children. *Sci Rep.* 2019;9(1):17714. doi:10.1038/s41598-019-53721-1
28. Jin Y-H, Cai L, Cheng Z-S, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). *Mil Med Res.* 2020;7. doi:10.1186/s40779-020-0233-6

29. Lineamiento clínico COVID-19 CCINSHAE 14feb2020.pdf.pdf. Google Docs.
Accessed May 3, 2020.
https://drive.google.com/file/d/1vge89Fuz_9RsgKk77XrpyG2RYW7NAGFP/view?usp=drive_open&usp=embed_facebook
30. Siordia JA. Epidemiology and clinical features of COVID-19: A review of current literature. *J Clin Virol Off Publ Pan Am Soc Clin Virol*. 2020;127:104357. doi:10.1016/j.jcv.2020.104357
31. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*. 1972;18(6):499-502.
32. Joshi SR, Anjana RM, Deepa M, et al. prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. *PloS One*. 2014;9(5):e96808. doi:10.1371/journal.pone.0096808
33. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. *Nat Clin Pract Endocrinol Metab*. 2009;5(3):150-159. doi:10.1038/ncpendmet1066
34. Choudhury KN, Mainuddin A, Wahiduzzaman M, Islam SMS. Serum lipid profile and its association with hypertension in Bangladesh. *Vasc Health Risk Manag*. 2014;10:327-332. doi:10.2147/VHRM.S61019
35. Jr DWH, Lemeshow S, Sturdivant RX. *Applied Logistic Regression*. John Wiley & Sons; 2013.
36. Meher G, Bhattacharjya S, Chakraborty H. Membrane Cholesterol Modulates Oligomeric Status and Peptide-Membrane Interaction of Severe Acute Respiratory Syndrome Coronavirus Fusion Peptide. *J Phys Chem B*. 2019;123(50):10654-10662. doi:10.1021/acs.jpcc.9b08455

37. Wang H, Yang P, Liu K, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. *Cell Res*. 2008;18(2):290-301. doi:10.1038/cr.2008.15
38. Glende J, Schwegmann-Wessels C, Al-Falah M, et al. Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2. *Virology*. 2008;381(2):215-221. doi:10.1016/j.virol.2008.08.026
39. Baglivo M, Baronio M, Natalini G, et al. Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity? *Acta Bio-Medica Atenei Parm*. 2020;91(1):161-164. doi:10.23750/abm.v91i1.9402
40. Lu Y, Liu DX, Tam JP. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. *Biochem Biophys Res Commun*. 2008;369(2):344-349. doi:10.1016/j.bbrc.2008.02.023
41. Strating JR, van Kuppeveld FJ. Viral rewiring of cellular lipid metabolism to create membranous replication compartments. *Curr Opin Cell Biol*. 2017;47:24-33. doi:10.1016/j.ceb.2017.02.005
42. Abu-Farha M, Thanaraj TA, Qaddoumi MG, Hashem A, Abubaker J, Al-Mulla F. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target. *Int J Mol Sci*. 2020;21(10). doi:10.3390/ijms21103544
43. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. *Am J Physiol Endocrinol Metab*. 2020;318(5):E736-E741. doi:10.1152/ajpendo.00124.2020

44. Yang H, Yang LC, Zhang RT, Ling YP, Ge QG. [Risks factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes]. *Beijing Da Xue Xue Bao*. 2020;52(3):420-424.
doi:10.19723/j.issn.1671-167X.2020.03.004
45. Basto-Abreu A, Barrientos-Gutiérrez T, Rojas-Martínez R, et al. [Prevalence of diabetes and poor glyceemic control in Mexico: results from Ensanut 2016.]. *Salud Publica Mex*. 2020;62(1):50-59. doi:10.21149/10752
46. Suárez V, Suarez Quezada M, Oros Ruiz S, Ronquillo De Jesús E. Epidemiología de COVID-19 en México: del 27 de febrero al 30 de abril de 2020. *Rev Clin Esp*. Published online May 27, 2020.
doi:10.1016/j.rce.2020.05.007
47. Xia X, Wen M, Zhan S, He J, Chen W. [An increased neutrophil/lymphocyte ratio is an early warning signal of severe COVID-19]. *Nan Fang Yi Ke Da Xue Xue Bao*. 2020;40(3):333-336. doi:10.12122/j.issn.1673-4254.2020.03.06
48. Shang W, Dong J, Ren Y, et al. The value of clinical parameters in predicting the severity of COVID-19. *J Med Virol*. Published online May 21, 2020.
doi:10.1002/jmv.26031